Joe Senn, PhD

Dr Senn is our Senior Vice President of Nonclinical Research and Development.

He has a long-standing track record of success in advancing breakthrough therapeutics into the clinic, having most recently served as SVP, Head of R&D, at SalioGen Therapeutics, where he oversaw the development of SalioGen’s first clinical candidate and non-viral gene therapy platform for the retina. Prior to his time at SalioGen, Dr Senn served as VP, Nonclinical Development, at Moderna Therapeutics, where he and his team were responsible for progressing more than 40 candidates into the clinic, including conducting the IND- and BLA-enabling nonclinical work for Spikevax®, Moderna’s COVID vaccine. Prior to Moderna, he was Site Head for Drug Safety at Takeda Pharmaceuticals, overseeing the development of all immunology products across the portfolio.

He earned his PhD in Pharmacology and Physiology from the University of Rochester School of Medicine and Dentistry and his BS from Niagara University.